The strong active-manager buying cluster, particularly Point72's massive increase, signals conviction in CG Oncology's pipeline catalysts. Monitor upcoming clinical data readouts and any insider selling that could indicate management taking advantage of the institutional demand. The 45-day 13F reporting lag means these positions may have already been adjusted — watch for Q4 2024 filings to confirm thesis persistence.
Executive Summary
A significant institutional cluster formed in CG Oncology during Q3 2024, with 14 buyers accumulating $41.7M in net new positions versus only 3 sellers trimming $5.5M. The buying was dominated by active managers and quant funds, led by Point72's $24.7M increase, suggesting a shared bullish thesis on the company's clinical-stage oncology pipeline.
Key Financial Metrics
Institutional Positions
Net institutional flow: $36.2M
▲ Buyers (14)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Point72 | DOUBLED | +575.7% | $28.1M | $24.7M |
| Schwab | DOUBLED | +114% | $14.3M | $8.7M |
| Driehaus Capital Management | ADD | +87% | $7.5M | $4.2M |
| Rafferty Asset Management | ADD | +54.2% | $3.0M | $1.4M |
| Rhumbline Advisers | ADD | +97.4% | $2.5M | $1.5M |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | TRIM | -34.6% | $15.5M | -$3.4M |
| Marshall Wace | NEAR_EXIT | -89.9% | $2.4M | -$2.1M |
| Russell Investments Group | NEAR_EXIT | -88.6% | $24.0K | -$20.9K |
Key Facts
- 14 institutional buyers added $41.7M in net new positions during Q3 2024
- Point72 (quant) more than 6x'd its stake, adding $24.7M to reach $28.1M
- Driehaus Capital Management added $4.2M, increasing position 87% to $7.5M
- Only 3 sellers trimmed $5.5M, led by Citadel reducing $3.4M and Marshall Wace exiting 90% of its $2.1M position
- Schwab (mega-passive) doubled its position, adding $8.7M to $14.3M
- Net institutional inflow of $36.2M across the cluster
Financial Impact
14 institutions accumulated $57.8M in holdings (net +$41.7M) while 3 sellers reduced holdings by $5.5M, resulting in a net institutional inflow of approximately $36.2M during Q3 2024
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Clinical-stage biotech carries binary risk from pipeline trial results
- Historical reports on CGON show negative average T+20 returns (-2.30%), suggesting the stock has been a poor performer despite institutional interest
- Point72's quant strategies can be momentum-driven and may reverse quickly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CGON-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | — |
Aug 6, 2026 8w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | — |
Jul 27, 2026 9w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | — |
Jul 17, 2026 11w ago | Insider Cluster | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | — |
Jul 16, 2026 11w ago | Court Ruling | $69.50 $74.71 | ▲ +7.50% | ▲ +3.88% | — |
Jun 24, 2026 14w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | — |
Jun 22, 2026 14w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | — |
Jun 12, 2026 16w ago | Institutional Cluster | $59.56 $75.24 | ▲ +26.33% | ▲ +24.55% | — |
May 26, 2026 18w ago | 8-K | $61.89 $70.25 | ▲ +13.50% | ▲ +15.45% | — |
May 15, 2026 20w ago | Press Release | $66.93 $59.56 | ▼ −11.01% | ▼ −13.13% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access